We have not explained this story yet. The original headline, summary and link are below.

Morgan Stanley downgraded Rentokil Initial to "Equal Weight" and cut its price target due to increased competition in North America from private equity-backed firms and changing customer behavior. This has led to higher acquisition costs and a decline in new customer acquisition for Rentokil, whose stock has fallen 32% this year. The company is undergoing restructuring and divesting non-core assets, with investors awaiting its third-quarter trading update.